Featured Research

from universities, journals, and other organizations

New Computer-aided Approach Tailors Drug Dose To Patient Needs

Date:
March 17, 2004
Source:
Penn State
Summary:
A computer-aided approach -- based on software-that-learns -- promises to provide a new tool that helps doctors tailor the dosage of abciximab, a medicine frequently used before angioplasty to lessen the chance of heart attack.

A computer-aided approach -- based on software-that-learns -- promises to provide a new tool that helps doctors tailor the dosage of abciximab, a medicine frequently used before angioplasty to lessen the chance of heart attack.

Related Articles


Dr. Mirna Urquidi-Macdonald, professor of engineering science and mechanics, says, "While we tried our approach first with abciximab, it may be applicable to other medicines that have a narrow therapeutical range between under dosing and overdosing."

The approach is described in the January issue of the journal, Clinical Pharmacology and Therapeutics. The authors are Urquidi-Macdonald, who worked on the project during a sabbatical at the National Institute on Aging, Gerontology Research Center in Baltimore, Md.; Dr. Donald E. Mager, National Institute on Aging, Gerontology Research Center, Baltimore, Md.; Dr. Mary A. Mascelli, Centocor Inc., Malvern, Pa.; Bart Frederick, Centocor, Inc., Malvern; Dr. Jane Freedman, Division of Cardiology, Boston University School of Medicine; Dr. Desmond J. Fitzgerald, The Royal College of Surgeons in Ireland; Dr. Neal S. Kleiman, Division of Cardiology, Baylor College of Medicine, Houston, Texas; and Dr. Darrell R. Abernethy, National Institute on Aging, Gerontology Research Center,.

The new approach is based on neural network software that can "learn" when given a large body of data on which to train. Using a fast back-propagation neural network and data from 8 patients undergoing coronary angioplasty and 30 healthy patients, the researchers trained the software to predict the best dose strategy for an individual patient based on 17 characteristics. These include, race, sex, age, weight, stable angina, previous myocardial infarction, diabetes, hypertension, hypercholesterolemia, smoking, prior coronary angioplasty, coronary artery bypass graft, statins, beta blocker, nitrates, calcium antagonists and diuretics.

Abciximab lessens the risk of heart attack by reducing the chance that a harmful blood clot will form by preventing blood cells, called platelets, from clumping together. Urquidi-Macdonald trained the software to predict the individual patient doses versus the time necessary to achieve 20 percent of the baseline platelet aggregation over 15 days.

"The key problem to solve was how to represent the data so that it included all of the patient's characteristics along with the concentrations of drug and platelet aggregation which change over time and to use a fast back propagation neural network designed for this application," Urquidi-Macdonald says.

The researchers solved the problem and also identified key patient characteristics that contribute significantly to establishing the abciximab dose-effect relationship. These characteristics include, among others, whether the patient smokes or not, ethnicity and the patient's weight.

By comparing the dosages predicted by the new system with dose-effect data from 39 patients who had undergone standard abciximab therapy, the researchers found that the new software offered potential for dose prescription improvement. For example, the software predictions suggest that the targeted degree of platelet inhibition may be achieved in some patients with lower doses, which could translate into a reduced risk for adverse side effects.

The Penn State researcher says, "The software also predicts that administering a smaller initial dose, followed by one or two infusions to keep the platelet concentration at 20 percent of baseline, achieves the same effect as giving the patient a larger initial dose."

In addition, the software predicted that two of the patients tested would not achieve the target response within the tested range of doses.

The researchers write, "The utility of this approach and whether it may provide an improvement in therapeutic outcomes clearly remain to be determined in a randomized, double-blind, prospective clinical trial."

Should the utility of the new approach be borne out in clinical trials, they predict that by using personal computers, laptops or personal digital assistants, clinicians could simply to enter the necessary input parameters to obtain a network-predicted regimen to aid in their decisions.

The project was supported by the Intramural Research Program of the National Institute on Aging. Clinical studies that provided the data for this analysis were supported by Centocor, Inc.


Story Source:

The above story is based on materials provided by Penn State. Note: Materials may be edited for content and length.


Cite This Page:

Penn State. "New Computer-aided Approach Tailors Drug Dose To Patient Needs." ScienceDaily. ScienceDaily, 17 March 2004. <www.sciencedaily.com/releases/2004/03/040317074943.htm>.
Penn State. (2004, March 17). New Computer-aided Approach Tailors Drug Dose To Patient Needs. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2004/03/040317074943.htm
Penn State. "New Computer-aided Approach Tailors Drug Dose To Patient Needs." ScienceDaily. www.sciencedaily.com/releases/2004/03/040317074943.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins